Novel concepts in the staging of renal cell carcinoma

Current Urology Reports

Volumn 4, Issue 1, 2003, Pages 41-48

  Leibovici, Dan ^b   Lindner, Arie ^b   Sella, Avishay ^a   Zisman, Amnon ^b  

^a ASSAF HAROFEH MEDICAL CENTER   (Israel)

^b NONE

Author keywords

Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Partial Nephrectomy; Radical Nephrectomy; Renal Cell Carcinoma

Indexed keywords

CANCER STAGING; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MORTALITY; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SURVIVAL; SURVIVAL RATE;

CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0037318386     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-003-0056-5     Document Type: Article

References (56)

1. Mickisch G, Carballido J, Hellsten S, et al.: Guidelines on renal cell cancer. Eur Urol 2001, 40:252–255. DOI: 10.1159/000049783
2. Greenlee R, Murray T, Bolden S, Wingo P: Cancer statistics. Ca Cancer J Clin 2000, 50:7–33.
3. Motzer R, Bander N, Nanus D: Renal-cell carcinoma. N Engl J Med 1996, 355:865–875. DOI: 10.1056/NEJM199609193351207
4. Elson PJ, Witte RS, Trump DL: Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988, 48:7310–7313.
5. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999, 161:381–386. DOI: 10.1016/S0022-5347(01)61897-4
6. Gelb A: Renal cell carcinoma current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:981–986. DOI: 10.1002/(SICI)1097-0142(19970901)80:5<981::AID-CNCR23>3.0.CO;2-R
7. Storkel S, Eble E, Adlanka K, et al.: Classification of renal carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:987–989. DOI: 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R
8. Mani S, Todd M, Katz K, Poo W: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995, 154:35–40. DOI: 10.1016/S0022-5347(01)67218-5
9. Kanamaru H, Sasaki M, Miwa Y, et al.: Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 1999, 83:222–226. DOI: 10.1046/j.1464-410x.1999.00912.x
10. Robson C, Churchill B, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969, 101:297–302.
11. Hermanek P, Schrott K: Evaluation of the new tumor, nodes and metastases classification of renal cell carcinoma. J Urol 1990, 144:238–241.
12. deKernion JB: Lymphadenectomy for renal cell carcinoma: therapeutic implications. Urol Clin North Am 1980, 7:697–703.
13. Guinan P, Sobin L, Algaba F, et al.: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80:992–993. DOI: 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q
14. Guinan P, Saffrin R, Stuhldreher D, et al.: Renal cell carcinoma: comparison of the TNM and Robson stage groupings. J Surg Oncol 1995, 59:186–189. DOI: 10.1002/jso.2930590310
15. Hafez K, Fergany A, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999, 162:1930–1933. This article is important for its recognition of the nephron-sparing surgical approach to RCC treatment. DOI: 10.1016/S0022-5347(05)68071-8
16. Belldegrun A, Tsui K, deKernion JB, Smith R: Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system. J Clin Oncol 1999, 17:2868–2875. This paper discusses the importance of nephron-sparing surgery in the treatment of RCC.
17. Javidan J, Stricker H, Tamboli P, et al.: Prognostic significance of the 1997 TNM classification of renal cell carcinoma. J Urol 1999, 162:1277–1281. DOI: 10.1016/S0022-5347(05)68264-X
18. Minervini R, Minervini A, Fontana N, et al.: Evaluation of the 1997 tumour, nodes and metastases classification of renal cell carcinoma: experience in 172 patients. BJU Int 2000, 86:199–202. DOI: 10.1046/j.1464-410x.2000.00826.x
19. Tsui K, Shvarts O, Smith R, et al.: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000, 163:1090–1095. DOI: 10.1016/S0022-5347(05)67699-9
20. Gettman M, Blute M, Spotts B, et al.: Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system. Cancer 2001, 91:354–361. DOI: 10.1002/1097-0142(20010115)91:2<354::AID-CNCR1009>3.0.CO;2-9
21. Gofrit ON, Shapiro A, Kovalski N, et al.: Renal cell carcinoma: evaluation of the 1997 TNM system and recommendations for follow-up after surgery. Eur Urol 2001, 39:669–674. DOI: 10.1159/000052525
22. Zisman A, Pantuck AJ, Chao D, et al.: Reevaluation of the 1997 TNM classification for renal cell carcinoma: T1 and T2 cutoff point at 4.5 rather than 7 cm better correlates with clinical outcome. J Urol 2001, 166:54–58. DOI: 10.1016/S0022-5347(05)66075-2
23. Igarashi T, Tobe T, Nakatsu HO, et al.: The impact of a 4 cm cutoff point for stratification of T1N0M0 renal cell carcinoma after radical nephrectomy. J Urol 2001, 165:1103–1106. DOI: 10.1016/S0022-5347(05)66437-3
24. Guinan P, Vogelzang N, Fremgen A, et al.: Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol 1995, 153:901–903. DOI: 10.1016/S0022-5347(01)67599-2
25. Ljungberg B, Grankvist K, Rasmuson T: Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer 1995, 76:1435–1439. DOI: 10.1002/1097-0142(19951015)76:8<1435::AID-CNCR2820760821>3.0.CO;2-Y
26. Hoffmann R, Franzke A, Buer J, et al.: Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer 1999, 79:1742–1745. DOI: 10.1038/sj.bjc.6690277
27. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540. This article outlines a modern integrated system for RCC prognostication.
28. Minasian L, Motzer RJ, Gluck L, et al.: Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 1993, 11:1368–1375.
29. Landonio G, Baiocchi C, Cattaneo D, et al.: Retrospective analysis of 156 cases of metastatic renal cell carcinoma: evaluation of prognostic factors and response to different treatments. Tumori 1994, 80:468–472.
30. de ForgesA, Rey A, Klink M, et al.: Prognostic factors of adult metastatic renal cell carcinoma: a multivariate analysis. Semin Surg Oncol 1988, 4:149–154. DOI: 10.1002/ssu.2980040302
31. Palmer P, Vinke J, Philip T, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992, 3:475–480.
32. Citterio G, Bertuzzi A, Tresoldi M, et al.: Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients. Eur Urol 1997, 31:286–291.
33. Fossa S, Kramar A, Droz J: Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994, 30A:1310–1314. DOI: 10.1016/0959-8049(94)90179-1
34. Neves R, Zincke H, Taylor W: Metastatic renal cell cancer and radical nephrectomy: identification of prognostic factors and patient survival. J Urol 1988, 139:1173–1176.
35. Canobbio L, Rubagotti A, Miglietta L, et al.: Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon alfa. J Cancer Res Clin Oncol 1995, 121:753–756. DOI: 10.1007/BF01213322
36. Lanigan D, McLean P, Murphy D, et al.: Ploidy and prognosis in renal carcinoma. Br J Urol 1993, 71:21–24. DOI: 10.1111/j.1464-410X.1993.tb15873.x
37. Eskelinen M, Lipponen P, Aitto-Oja L, et al.: The value of histoquantitative measurements in prognostic assessment of renal adenocarcinoma. Int J Cancer 1993, 55:547–554. DOI: 10.1002/ijc.2910550405
38. Wu S, Hafez G, Xing W, et al.: The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma. Cancer 1996, 77:1154–1160. DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1154::AID-CNCR23>3.0.CO;2-#
39. Moch H, Presti JC Jr, Sauter G, et al.: Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 1996, 56:27–30.
40. Elfving P, Mandahl N, Lundgren R, et al.: Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol 1997, 80:698–706.
41. Tannapfel A, Hahn H, Katalinic A, et al.: Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996, 77:164–171. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<164::AID-CNCR27>3.0.CO;2-2
42. Moch H, Sauter G, Gasser T, et al.: p53 protein expression but not mdm-2 protein expression is associated with rapid tumor cell proliferation and prognosis in renal cell carcinoma. Urol Res 1997, 25(Suppl 1):S25-S30. DOI: 10.1007/BF00942044
43. Moch H, Sauter G, Buchholz N, et al.: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 1997, 28:1255–1259. DOI: 10.1016/S0046-8177(97)90198-2
44. Lipponen P, Eskelinen M, Hietala K, et al.: Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma. Int J Cancer 1994, 57:275–280. DOI: 10.1002/ijc.2910570224
45. Uhlman D, Nguyen P, Manivel J, et al.: Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1995, 1:913–920.
46. Uhlman D, Nguyen P, Manivel J, et al.: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J Natl Cancer Inst 1994, 86:1470–1475. DOI: 10.1093/jnci/86.19.1470
47. Bot F, Godschalk J, Krishnadath K, et al.: Prognostic factors in renal-cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int J Cancer 1994, 57:634–637. DOI: 10.1002/ijc.2910570504
48. Yoshino S, Kato M, Okada K: Clinical significance of angiogenesis, proliferation and apoptosis in renal cell carcinoma. Anticancer Res 2000, 20:591–594.
49. Wittke F, Hoffmann R, Buer J, et al.: Interleukin 10 (IL-10): an immunosupressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br J Cancer 1999, 79:1182–1184. DOI: 10.1038/sj.bjc.6690189
50. Blay J, Negrier S, Combaret V, et al.: Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992, 52:3317–3322.
51. Kattan MW, Reuter V, Motzer RJ, et al.: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001, 166:63–67. This publication discusses an integrated system for localized RCC prognostication. DOI: 10.1016/S0022-5347(05)66077-6
52. Kovacs G, Akhtar M, Beckwith B, et al.: The Heidelberg classification of renal cell tumours. J Pathol 1997, 183:131–133. DOI: 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
53. Zisman A, Pantuck AJ, Dorey F, et al.: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001, 19:1649–1657. This article is important because it discusses an integrated system for prognostication of localized and metastatic RCC.
54. Nadas A: On proportional hazards functions. Technometrics 1970, 12:413–418. DOI: 10.2307/1267247
55. Zisman A, Pantuck AJ, Dorey F, et al.: Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol 2002, 20:1368–1374. DOI: 10.1200/JCO.20.5.1368
56. Slaton J, Zisman A, Belldegrun AS, et al.: Validation of UCLA Integrated Staging System (UISS) as a predictor for survival in patients undergoing nephrectomy for renal cell carcinoma. Paper presented at the American Urological Association Annual Meeting. Orlando, FL. May 22–30, 2002.